41 Pathologic Complete Response (pCR) Rates According to MammaPrint and BluePrint Test Results Are Consistent Among Pre and Postmenopausal Patients

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement38th Annual Miami Breast Cancer Conference® - Abstracts
Volume 35
Issue suppl 1
Pages: 35-36

Pat Whitworth, MD1

1Ascension Saint Thomas Hospital Midtown, Nashville, TN.

Background

Increased use of multigene expression profiling has enabled refinement of early-stage breast cancer management. Clinical trials have demonstrated that risk-of-recurrence testing identifies those patients with breast cancer who will derive benefit from adjuvant chemotherapy and those who can avoid it without affecting long-term clinical outcomes. Recent subanalyses of premenopausal patients suggest a significant clinical benefit to adjuvant chemotherapy in this patient group; however, it has yet to be demonstrated whether this is due to a direct cytotoxic effect or secondary ovarian suppression. Here, we report the first age-based analysis of the 70-gene (MammaPrint; MP) and 80-gene (BluePrint; BP) assays in the preoperative setting.

Materials and Methods

The prospective NBRST trial (NCT0147910) evaluated the utility of MP and BP in the preoperative treatment setting. From 2011 to 2014, the study enrolled 1072 patients from 67 institutions and included women with invasive breast cancer of any pathology-defined subtype, regardless of hormone or HER2 receptor status. Patients received neoadjuvant chemotherapy or neoadjuvant endocrine therapy, according to National Comprehensive Cancer Network guideline recommendations. Median follow-up for distant metastasis–free survival was 5.0 years.

Results

In the study, 41.8% of patients were 50 years or younger and 58.2% were aged >50 years. MP classified 16% of patients as low risk and 84% of patients as high risk. BP classified 49.2% of tumors as luminal, 16.2% as HER2 positive, and 34.6% as basal subtype. MP further stratified luminal tumors into A (32.6%) and B (67.4%) subtypes. MP classified 13.8% of patients <50 years and 18.1% of patients aged >50 years as low risk. Among the 4 molecular subtypes, there was no significant difference in pathologic complete response rate based on an age-50 cutoff (Table).

Conclusions

As expected, pCR rates varied according to molecular subtype. MP and BP accurately predicted pCR in patients with tumors of all subtypes, regardless of age, supporting their use to better tailor preoperative treatment and timing for surgery.

Articles in this issue

1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
45 Neoadjuvant Chemotherapy Use in Elderly Patients
45 Neoadjuvant Chemotherapy Use in Elderly Patients
Related Content